A new clinical trial by Moderna has revealed that a combined flu and coronavirus vaccine elicits a higher immune response compared to administering the vaccines separately.
This innovative two-in-one jab, currently under trial, could revolutionize how seasonal illnesses are managed, providing better protection and greater convenience.
Higher Immune Response
The clinical trial, involving 8,000 participants, demonstrated that the combined vaccine, known as mRNA-1083, significantly increased antibody responses against both influenza and Covid-19.
The trial was randomized and controlled, with participants split into two groups: one group aged 65 and over and the other aged 50 to 64. These results are promising, suggesting that the combined vaccine could be more effective than the current separate vaccines in use.
Potential for Approval and Availability
Moderna’s CEO, Stéphane Bancel, expressed optimism about the future availability of the vaccine. “Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses,” he said.
By the 2025 or 2026 flu season, the company wants the vaccine to be available and approved by regulators.
Clinical Trial Details
The phase 3 trial compared the new combined vaccine to existing vaccines, such as Moderna’s Spikevax for COVID-19, and flu vaccines like Fluzone and Fluarix.
The findings indicated that the mRNA-1083 vaccine not only matched but, in many cases, surpassed the immune responses elicited by the separate vaccines. This is particularly significant as it is the first time a company has published final phase 3 data for a combined flu and COVID-19 vaccine.
Implications for Public Health
The introduction of a combined vaccine could simplify vaccination schedules, potentially increasing compliance and coverage rates.
The findings have bigger effects, according to Dr. Philip Cruz, UK Medical Director at Moderna: “The phase three trial results for mRNA-1083, Moderna’s combination vaccine targeting influenza and COVID-19, have met the primary endpoints, showing a higher immune response in adults over 50 compared to existing flu and COVID vaccines.”
Enhanced Convenience and Protection
Currently, the NHS uses Moderna’s Spikevax and Pfizer-BioNTech’s Comirnaty for COVID-19 booster programs. The new combined vaccine would mean that people need only one jab instead of two, providing a more convenient option without compromising on protection.
Moderna’s findings also showed that the mRNA-1083 vaccine is likely more effective because it is designed to combat more recent virus variants.
Future Prospects
The positive results from this trial pave the way for regulatory approval and potential inclusion in national vaccination programs. The NHS could start using the combined vaccine as early as the next few years, subject to regulatory approval.
This development follows a broader trend of pharmacies and health services offering more flexible vaccination options, like Boots offering the Pfizer-BioNTech vaccine over the counter.
Expert Opinions
Professor John Tregoning, Professor of Vaccine Immunology at Imperial College London, noted the significance of these findings. He stated that the new vaccine appears to produce robust anti-influenza and anti-Covid antibodies.
While the press release provided a high-level summary, the detailed data supports the conclusion that the combined vaccine could be a major advancement in public health.
Moderna’s new combined flu and COVID-19 vaccine represents a significant advancement in vaccine technology. With the potential to provide stronger protection and greater convenience, this innovative jab could play a crucial role in reducing the burden of respiratory viruses.
As regulatory approval processes advance, the hope is that this combined vaccine will soon be available to the public, offering a new standard in seasonal illness protection.
The information is taken from CNBC and Daily Mail
